

**PSC NO: 9 GAS**

LEAF: 177

**COMPANY: CONSOLIDATED EDISON COMPANY OF NEW YORK, INC.**

REVISION: 14

INITIAL EFFECTIVE DATE: 02/27/2022

SUPERSEDING REVISION: 13

**GENERAL INFORMATION - Continued****IX. Special Adjustments - Continued****5. Research and Development Surcharge Applicable to Firm Customers**

In accordance with the Public Service Commission Order issued February 14, 2000 in Case 99-G-1369 and modified by Commission Order issued February 21, 2014 in Case 13-G-0031, all Firm Sales and Firm Transportation Customers will be subject to a research and development ("R&D") surcharge to provide funding for R&D projects.

**6. Unbilled Fees Adjustment**

The Company will recover or credit the reconciliation of all costs related to deferred late payment fees and other fees originally associated with customer non-payment ("Unbilled Fees") for Rate Year One (i.e., 2020) as authorized by the Commission in Case 19-G-0066. The Company will recover these Unbilled Fees commencing December 1, 2021, through December 31, 2022. The Company will reconcile the approved fees in Rate Years Two (i.e., 2021) and Three (i.e., 2022) in Case 19-G-0066 without any threshold requirement and charge/credit any variance. The Company will begin its charge or credit of the approved fees for Rate Year Two on January 1, 2023, through December 31, 2023 and for Rate Year Three on January 1, 2024, through December 31, 2024. The Company will reconcile the actual annual late payment fee revenues with Commission approved levels included in base rates in 2023 and future years and charge/credit any variance over a subsequent twelve-month period as authorized by the Commission.

The Unbilled Fees Adjustment mechanism on the MRA statement is applicable to Firm Sales and Firm Transportation Customers. Any over- or under-recovery shall be included in a subsequent Unbilled Fees Adjustment.

(General Information - Continued on Leaf No. 178)

**Issued By: Robert Hoglund, Senior Vice President & Chief Financial Officer, 4 Irving Place, New York, NY 10003**

Suspended to 06/27/2022 by order in Case 22-G-0065. See Supplement No. 93. The supplement filing date was 02/17/2022.  
Suspended to 12/27/2022 by order in Case 22-G-0065. See Supplement No. 94. The supplement filing date was 06/09/2022.  
Suspended to 04/26/2023 by order in Case 22-G-0065. See Supplement No. 95. The supplement filing date was 12/14/2022.  
Suspended to 07/25/2023 by order in Case 22-G-0065. See Supplement No. 96. The supplement filing date was 04/24/2023.  
Cancelled by supplement No. 97 effective 07/24/2023